DaVita

DaVita Gross Margin

The Gross Margin of DaVita (DVA) as of Nov 1, 2026 is 27.00 %. In the previous year, Gross Margin was 32.91 % — a change of -17.93% (lower).

Gross Margin

27.00 %

YoY

-17.93%

Last updated:

Gross Margin of DaVita is 2025 27.00 % . Gross Margin of DaVita was 2024 32.91 % . It decreases by -17.93% lower compared to the previous year.

For DaVita, the gross margin of 27.0% is down versus 31.4% a few years ago.

The DaVita Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
28.14 USD
Jan 1, 2019
30.50 USD
Jan 1, 2020
30.84 USD
Jan 1, 2021
31.38 USD
Jan 1, 2022
29.29 USD
Jan 1, 2023
31.47 USD
Jan 1, 2024
32.91 USD
Jan 1, 2025
27.00 USD
The DaVita Gross Margin history
YEARGross MarginYoY
27.00 %-17.93%
32.91 %+4.56%
31.47 %+7.45%
29.29 %-6.68%
31.38 %+1.77%
30.84 %+1.09%
30.50 %+8.40%
28.14 %-5.44%
29.76 %+33.94%
22.22 %-2.06%
22.68 %-21.04%
28.73 %+9,378.15%
0.30 %-4.67%
0.32 %+2.92%
0.31 %+11.16%
0.28 %-8.73%
0.30 %-0.93%
0.31 %-3.34%
0.32 %+4.13%
0.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DaVita Stock analysis

What does DaVita do? DaVita Inc. is a company headquartered in Denver, Colorado, specializing in the provision and management of outpatient dialysis treatments (renal replacement therapy) and related services. The company was founded in 1999 and has since experienced impressive growth, with a presence in over ten countries worldwide. The history of DaVita traces back to the origin of its business model: outpatient dialysis treatment. This is a form of renal replacement therapy where patients can be treated outside of the hospital, in a dedicated center or even in their own homes. This type of dialysis is less intimidating compared to inpatient treatment in a hospital and can be much more flexible in terms of scheduling. DaVita took this idea and brought it to the market in the US and other countries, where it has proven to be extremely successful. Nowadays, DaVita operates in three main business segments. The first is the patient care segment, which focuses on providing dialysis treatments and related services. Here, DaVita offers outpatient dialysis centers where patients can receive regular treatment. Another important aspect of this segment is patient and family education, integrating them into the treatment process and helping them lead as normal a life as possible. The second core area is the pharmaceutical supply business. DaVita has an extensive network of facilities and suppliers, as well as its own pharmacies where the necessary medications for dialysis patients are manufactured and stored. DaVita also handles billing with insurance and other payment entities to ensure seamless patient care. The third core area of DaVita is the international supply company. Here, DaVita offers its services in over ten countries worldwide, including Mexico, Colombia, Brazil, Saudi Arabia, and Canada. DaVita has steadily expanded its international business in recent years and aims to have a presence in even more countries in the future. But DaVita does not limit itself to these three core areas. The company is also known for its innovative research and development efforts aimed at improving the treatment of kidney disease and developing new technologies. Products offered by DaVita include innovative dialysis devices, advanced care management software, and intelligent sensors for automated patient monitoring. In its over 20-year history, DaVita has overcome many challenges, including regulatory issues, economic fluctuations, and ever-growing competition. Despite these challenges, the company has steadily expanded its position in the industry and established itself as a leading provider of dialysis and related services. DaVita's success is based on a culture of results orientation and a strong commitment to improving patient outcomes. The company understands that each patient has unique needs and that the treatment of kidney disease requires a lifelong commitment. Therefore, DaVita emphasizes individual care and collaboration with patients and their families to ensure optimal care. Overall, DaVita is an innovative company specializing in the provision of dialysis treatments and related services. The company has overcome many challenges in its history and established itself as a leading provider of dialysis and related services. DaVita is committed to improving the quality of life for dialysis patients worldwide and continuously optimizing the treatment of kidney disease. DaVita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaVita stock

Gross Margin of DaVita is 27.00 % in 2025.

Gross Margin of DaVita changed from 32.91 % to 27.00 %, representing a -17.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin DaVita since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's DaVita with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DaVita

All Key Metrics — DaVita